Biotech Values

[DewDiligence]

Roche anti-TIGIT compound fails phase-3 in SCLC:

https://www.businesswire.com/news/home/20220329005953/en

Genentech, a member of the Roche Group…today announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. The co-primary endpoint of overall survival was not met at its interim analysis and is unlikely to reach statistical significance at the planned final analysis.

Several other companies including GILD/RCUS, NVS, and MRK have anti-TIGIT programs.